Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Provided By GlobeNewswire
Last update: Nov 12, 2024
U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025
Read more at globenewswire.com7.92
+0.16 (+2.06%)
3.32
-0.11 (-3.21%)
Find more stocks in the Stock Screener
